Intravenous N-acetyl-cysteine (NAC) for Prevention of Post-embolization Syndrome in Hepatocellular Carcinoma
Phase 3
- Conditions
- Hepatocellular CarcinomaTransarterial Chemoembolization
- Registration Number
- TCTR20150313002
- Lead Sponsor
- Faculty of Medicine, Thammasat University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
- Patients with a diagnosis of hepatocellular carcinoma (HCC) and subjected to treat with chemoembolization (TACE) ( The diagnosis of HCC is based on (American association of liver diseases (AASLD) guidelines 2010)
- Age 18-65 years
- No contraindication to N-acetyl-cysteine
Exclusion Criteria
- Receiving other treatment within 6 months duration (e.g. radiofrequency ablation (RFA) or surgical liver resection)
- Having severe underlying illness e.g. ESRD, cardiac disease, AIDS, etc.
- Pregnancy or lactation
- Receiving possible drug interaction with NAC e.g. Nitroglycerine
- Denial to participate the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Post-embolisation syndrome 72 hours Symptomatic assessment and laboratory investigation
- Secondary Outcome Measures
Name Time Method Hepatic decompensation 72 hours Symptomatic assessment and laboratory investigation